title: Direct oral anticoagulants in rare venous thrombosis.
abstract: The direct inhibitors of thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban) are currently used in patients with venous thrombosis of the lower or upper limbs or with pulmonary embolism. However, the use of these direct oral anticoagulants (DOACs) in subjects with abdominal or cerebral venous thrombosis is more contentious due to the paucity of available data. In a few case reports and small series of patients hitherto published, the DOACs showed good efficacy and safety, supporting an extension of their use to these rare conditions. Thus, prospective cohort studies and randomized controlled trials have been set up. In this article, we review the published clinical experience with DOACs in rare venous thrombosis, and provide updated information on ongoing clinical trials.
authors.affiliation: USS Malattie Mieloproliferative Croniche, USC Ematologia, Ospedale Papa Giovanni XXIII, Piazza OMS 1, 24127, Bergamo, Italy. gfinazzi@hpg23.it.
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi dell'Insubria, Varese, Italy.
authors.forename: Walter
authors.initials: W
authors.lastname: Ageno
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D000069604:Dabigatran / Q000627:therapeutic use*; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D000069552:Rivaroxaban / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D011720:Pyrazoles; D011728:Pyridones; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran
keywords: Abdominal venous thrombosis; Apixaban; Cerebral venous thrombosis; Dabigatran; Rivaroxaban